Journal of Functional Foods, Journal Year: 2024, Volume and Issue: 123, P. 106595 - 106595
Published: Nov. 26, 2024
Language: Английский
APOPTOSIS, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 4, 2025
Colorectal cancer (CRC) represents a significant global health burden, with chemotherapy resistance representing challenge to effective treatment. SEC23A, core component of the COPII vesicle trafficking system, is critical importance regard protein transport and cellular homeostasis. Nevertheless, its function in CRC progression chemoresistance remains uncertain. The present study investigates correlation between SEC23A expression sensitivity 5-fluorouracil (5-FU), widely used chemotherapeutic agent, particular emphasis on ER stress-induced apoptosis. A bioinformatic analysis was conducted evaluate association patient prognosis. Chemotherapy predicted using GDSC data validated experimentally cell lines manipulated expression. In order explore role acquired drug resistance, patient-derived xenograft (PDX) models 5-FU-resistant were employed. Apoptosis assays, cycle analysis, stress modulation experiments performed elucidate underlying mechanisms. significantly reduced samples compared normal tissues. This reduction linked poorer prognosis, including both overall disease-specific survival. observed low increased 5-FU, as evidenced by predictions vitro experiments. PDX models, metastatic lesions exhibited decreased following 5-FU treatment comparison primary tumors. Overexpression restored Bioinformatic experimental analyses revealed robust stress-related apoptotic pathways. Elevated facilitate accumulation misfolded proteins response treatment, which turn resulted plays crucial modulating cells regulating Its downregulation contributes chemoresistance, indicating that may serve prognostic marker therapeutic target CRC. Strategies aimed at upregulating or enhancing provide new avenues for overcoming improving outcomes patients.
Language: Английский
Citations
1
Cardiovascular Toxicology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 18, 2025
Language: Английский
Citations
0
Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16
Published: April 17, 2025
Doxorubicin (DOX) has received widespread attention as a broad-spectrum antitumor drug. However, it been recognized challenge that long-term DOX injections can lead to severe cardiotoxicity. There are numerous interventions DOX-induced cardiotoxicity, and the most cost-effective is phytochemicals. It reported phytochemicals have complex diverse biological properties, facilitating mitigation of cardiotoxicity pathological mechanisms, nod-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome-mediated cardiomyocyte pyroptosis one them. This review initially presents an overview mechanisms underlie induced by DOX. Subsequently, we present comprehensive elucidation structure activation NLRP3 inflammasome. Finally, provide detailed summary mitigate influencing expression inflammasome in cardiomyocytes.
Language: Английский
Citations
0
Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(5), P. 681 - 681
Published: May 3, 2025
Cancer remains the second leading cause of death worldwide. Doxorubicin (DOX) is a cornerstone hematologic malignancy treatment, but it limited by its dose-dependent cardiotoxicity, to systolic and diastolic cardiac dysfunction and, ultimately, dilated hypokinetic cardiomyopathy. Cardio-oncology has emerged as subspecialty addressing cardiovascular complications in cancer patients, highlighting preventive therapeutic strategies reduce therapy-related (CTRCD). Current approaches, including beta-blockers, renin–angiotensin system (RAS) inhibitors, statins, offer partial cardioprotection. Sodium-glucose cotransporter-2 (SGLT2) initially developed for type 2 diabetes mellitus (T2DM), demonstrate pleiotropic cardioprotective effects beyond glycemic control, reduced oxidative stress, inflammation, myocardial remodeling. This review explores interplay between anthracycline therapy, particularly DOX, cardiotoxicity while evaluating SGLT2 inhibitors novel agents cardio-oncology. Preclinical studies suggest attenuate CTRCD preserving mitochondrial function inhibiting apoptosis, clinical trials highlight their efficacy reducing heart failure (HF) hospitalizations (CV) mortality. Integrating into cardio-oncology protocols could revolutionize management CTRCD, enhancing patient outcomes oncology care. Considering emerging evidence, may provide significant benefits patients undergoing those with elevated risk profiles. We recommend that future prospective, large-scale further evaluate safety these therapy optimize individualized treatment strategies.
Language: Английский
Citations
0
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2025, Volume and Issue: unknown, P. 167898 - 167898
Published: May 1, 2025
Language: Английский
Citations
0
Journal of Functional Foods, Journal Year: 2024, Volume and Issue: 123, P. 106595 - 106595
Published: Nov. 26, 2024
Language: Английский
Citations
0